Cabergoline

Drug Profile

Cabergoline

Alternative Names: Cabaser; CG 101; Dostinex; FCE 21336; PNU 142799

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Kissei Pharmaceutical
  • Class Antiparkinsonians; Ergolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Galactorrhoea; Hyperprolactinaemia; Parkinson's disease
  • Discontinued Breast cancer; Pituitary cancer; Restless legs syndrome

Most Recent Events

  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 13 Sep 2004 A study has been added to the adverse events and Parkinson's disease therapeutic trials sections
  • 27 Aug 2003 A study has been added to the adverse events and Parkinson's disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top